Pure Global

Comparison of the effect of intravenous and intra-cuff magnesium on post-extubation tracheal morbidity. - Trial PACTR202211634990263

Access comprehensive clinical trial information for PACTR202211634990263 through Pure Global AI's free database. This Not Applicable trial is sponsored by Dr Naa Martekuor Vanderpuye and is currently Completed. The study focuses on Surgery; Anaesthesia.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
PACTR202211634990263
Not Applicable
Completed
Trial Details
Pan Africa Clinical Trials Registry โ€ข PACTR202211634990263
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Comparison of the effect of intravenous and intra-cuff magnesium on post-extubation tracheal morbidity.

Study Focus

Surgery; Anaesthesia

Sponsor & Location

Dr Naa Martekuor Vanderpuye

Dr. Naa Martekuor Vanderpuye

Ghana

Timeline & Enrollment

Not Applicable

Apr 15, 2022

Oct 06, 2022

Summary

Post extubation tracheal morbidity is a common complication after tracheal intubation . Its incidence ranges from 14-90% (2)(1) following endotracheal intubation and 5.8-34% after laryngeal mask insertion . Laryngotracheal morbidities following ETT extubation are associated with several negative outcomes including patient dissatisfaction, increased length of hospital stay, increased hospital cost and reduced bed turnover. Several studies have identified various means of reducing the occurrence of these morbidities . Amongst these findings are improvements in laryngoscopes and endotracheal tube properties(5), intra-cuff and intravenous lidocaine, topical airway and intravenous steroids, gargled NSAIDโ€™s nebulised and intravenous Ketamine. Magnesium which has anti-nociceptive and anti-inflammatory properties and can therefore play a role in reducing post extubation laryngotracheal morbidity. It is therefore not surprising to see the use of intravenous magnesium sulphate in preventing post extubation laryngotracheal morbidities in literature. Literature however does not show intra-cuff magnesium being proposed as a preventive measure for post extubation laryngotracheal morbidities.Objectives: 1. To determine and compare the incidence and severity of post-extubation laryngotracheal morbidity (sore throat, cough and hoarseness of voice) between patients who will have their ETT cuff filled with air, patients who will have their ETT cuffs filled with 2g Magnesium Sulphate and patients who will have their ETT cuffs filled with air and in addition receive 2g intravenous magnesium sulphate at induction. 2.To determine and compare the hemodynamic changes (Heart rate and Blood Pressure) during tracheal extubation between patients who will have their ETT cuff filled with air, patients who will have their ETT cuffs filled with 2g Magnesium Sulphate and patients who will have their ETT cuffs filled with air and in addition receiving 2g if intravenous magnesium sulphate.

ICD-10 Classifications

Other complications of anaesthesia
Anaesthetic, unspecified
During surgical operation
During surgical operation
During surgical operation

Data Source

Pan Africa Clinical Trials Registry

PACTR202211634990263

Non-Device Trial